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Pathways controlling cell proliferation and cell survival require
flexible adaptation to environmental stresses. These mechanisms
are frequently exploited in cancer, allowing tumor cells to thrive in
unfavorable milieus. Here, we show that Hsp90, a molecular
chaperone that is central to the cellular stress response, associates
with survivin, an apoptosis inhibitor and essential regulator of
mitosis. This interaction involves the ATPase domain of Hsp90 and
the survivin baculovirus inhibitor of apoptosis repeat. Global
suppression of the Hsp90 chaperone function or targeted Ab-
mediated disruption of the survivin–Hsp90 complex results in
proteasomal degradation of survivin, mitochondrial-dependent
apoptosis, and cell cycle arrest with mitotic defects. These data link
the cellular stress response to an antiapoptotic and mitotic check-
point maintained by survivin. Targeting the survivin–Hsp90 com-
plex may provide a rational approach for cancer therapy.
Tumor cells exhibit extraordinary plasticity to adapt to noxiousstimuli and thrive in unfavorable environments. This typi-
cally involves increased resistance to apoptosis (1) by deregu-
lated overexpression of cell death antagonists of the Bcl-2 (2) or
inhibitor of apoptosis (IAP) gene family (3) or loss of cell death
activatorseffectors (4, 5). Another hallmark of cancer that
promotes enhanced adaptation to environmental challenges is a
constitutive up-regulation of the cellular stress response. This
preserves folding of nascent polypeptides (6), prevents protein
aggregation (7), and ensures specialized intracellular trafficking
of client proteins (8). The protein folding quality control ma-
chinery is orchestrated by heat shock proteins (Hsps), a family
of evolutionary conserved ATPase-directed molecular chaper-
ones (9). In particular, Hsp90 (10, 11) controls the balance
between foldingmaturation (12) and proteasomal destruction
(13) of a restricted number of client proteins (14) that are
typically involved in signal transduction and cell proliferation
(15). This pathway is exploited in cancer where Hsp90 is
up-regulated (16) and may be linked to resistance to apoptosis
(17) by inhibition of caspase-9 activation (18), induction of
antiapoptotic Bcl-2 (19), or stabilization of survival kinases
RIP-1 (20) or Akt (21). In this context, Hsp90 antagonists are
being explored as novel cancer therapeutics (22).
Here, we show that Hsp90 associates with survivin (23), an
IAP family protein (3) overexpressed in nearly every human
tumor, and with essential roles in mitotic control and apoptosis
inhibition (23). Disruption of the survivin–Hsp90 interaction
destabilizes survivin, initiates mitochondrial apoptosis, and sup-
presses cell proliferation, suggesting its potential suitability for
cancer therapies.
Materials and Methods
Abs. Abs to survivin were from Novus Biologicals (Littleton, CO)
(24). Abs to Hsp90 or -tubulin were from Transduction Lab-
oratories (Lexington, KY) and Sigma, respectively. Abs to
hemagglutinin or FLAG were from Roche and Sigma, respec-
tively. An Ab to caspase-9 was from Cell Signaling Technology
(Beverly, MA).
Cell Lines and Constructs. Cervical carcinoma HeLa or B lympho-
blastoid Raji cells were from the American Type Culture Col-
lection. A YUSAC-2 melanoma cell line stably transfected to
express survivin on withdrawal of tetracycline (Tet) was de-
scribed (25). WT or Apaf-1/ mouse embryonic fibroblasts
(MEF) were described (26). Hsp90 full-length (1–732) or the
three fragments N (1–272), M (273–617), or C (629–732) were
cloned by PCR in pGex-4T3 (Amersham Biosciences) and
pFLAG-cytomegalovirus 6c (Sigma). A survivin Cys-843Ala
mutant [survivin(C84A)] was described (27). Recombinant pro-
teins were expressed in Escherichia coli and purified as described
(24). A CD11b integrin I domain was used as a control.
Affinity Chromatography, Coimmunoprecipitation, and Western Blot-
ting. HeLa cell (1.5  108) extracts were applied to 0.5 ml of
CNBr-activated Sepharose 4B (Amersham Biosciences) coupled
to 5 mg of a polyclonal Ab to survivin. The bound material was
eluted in 0.1 M glycine (pH 2.5) and neutralized in 1 M Tris (pH
8.0), and fractions were analyzed by Western blotting. Immu-
noprecipitation experiments from Raji (5  105) or HeLa (2 
105) cell extracts followed by Western blotting of the immune
complexes were carried out as described (24). HeLa cells trans-
fected with GFP-survivin or GFP-survivin(C84A) were treated
with cycloheximide (100 gml), harvested after 0–60 min, and
analyzed by Western blotting with an Ab to GFP. For heat shock,
HeLa cells (2.5 105) were submerged in a preheated water bath
for 1 h at 42°C and analyzed by Western blotting or DNA content
during an 11-h recovery period at 37°C. To inhibit the chaperone
function of Hsp90, HeLa, MEF, or YUSAC-2 cells (25) were
treated with geldanamycin (GA, 0–10 M, Sigma) with or
without 5 M of the proteasome inhibitor, lactacystin (Calbio-
chem), and analyzed after 24 h by Western blotting or cell cycle
progression. HeLa cells treated with GA were simultaneously
analyzed for in vivo caspase activity (CaspaTag, Intergen, Pur-
chase, NY) and plasma membrane integrity by propidium iodide
staining and multiparametric f low cytometry. For in vivo pull-
downs, HeLa cells treated with or without microtubule-
stabilizing taxol (Sigma, 2 M for 16 h) were harvested and
incubated with survivin-Sepharose (3 mgml), and bound pro-
teins were analyzed by Western blotting.
StructureFunction of Survivin–Hsp90 Interaction. For in vitro pull-
downs, 10 g of GST or GST fusion proteins bound to gluta-
thione beads (20 l) were incubated with recombinant survivin
(30, 100, and 300 ng) and washed, and pellets or supernatants
were analyzed by Western blotting. ELISA was carried out as
described (24) by using survivin or Hsp90 (10 gml) immobi-
lized on microtiter wells (Dynatech). For peptide competition,
Hsp90 (2.5 mgml) was incubated with overlapping synthetic
peptides (24) duplicating the survivin sequence 1–101 (20 g
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ml) for 16 h at 4°C, before determination of binding to survivin,
by ELISA. For Ab competition, survivin (300 ng) was incubated
with mAbs 58 or 8E2 (24) or IgG (3 g) for 1 h at 22°C before
addition to GST-Hsp90 or GST-N Hsp90 and analysis of bound
proteins by Western blotting.
Intracellular Targeting of Survivin–Hsp90 Interaction. HeLa cells
(2  105) were loaded with 5 g of mAbs 8E2 or 58 to survivin
(24) or mouse IgG in OptiMEM (Life Technologies, Grand
Island, NY), in the presence of BioPorter protein transfection
reagent (Gene Therapy Systems, San Diego). After 4 h, cells
were supplemented with 100 gml cycloheximide and analyzed
(0–90 min) for survivin expression by Western blotting. The
efficiency of Ab loading (90%) was determined by using FITC-
conjugated IgG (5 g) and fluorescence microscopy. Trans-
duced HeLa or YUSAC-2 cells with or without Tet were
analyzed for caspase-9 processing by Western blotting or in vivo
caspase activity by flow cytometry (CaspaTag, Intergen).
Immunofluorescence Analysis. HeLa cells loaded with mAbs 58 or
8E2 to survivin or IgG were stained with a mAb to -tubulin and
analyzed by fluorescence microscopy. The mitotic index was
calculated by counting mitotic cells at 400 magnification in at
least five fields containing an average of 100 cells per field.
Statistical Analysis. Data were analyzed by using the paired t test
on a PRISM software package for Windows (GraphPad, San
Diego). A P value of 0.05 was considered statistically significant.
Results and Discussion
Identification of a Survivin–Hsp90 Interaction. We tested the effect
of heat shock on expression levels of the IAP family (3) protein,
survivin (23). A 42°C heat shock of HeLa cells caused time-
dependent increase in survivin expression by Western blotting
(Fig. 1A). This coincided with up-regulation of the inducible
form of Hsp70, 4–11 h after heat shock, whereas Hsp90 only
moderately increased, and -actin levels remained unchanged
(Fig. 1 A). Heat shock did not induce changes in cell cycle
progression or G2M arrest in HeLa cells (Fig. 1B), indicating
that the induction of survivin under these conditions was inde-
pendent of cell cycle transitions. To search for regulators of the
survivin heat shock response, we coupled an Ab that recognizes
the different subcellular pools of survivin (24) to Sepharose
beads and fractionated HeLa cell extracts. A major band at 90
kDa coeluted with survivin and was identified as Hsp90 by
Western blotting (Fig. 1C). Tubulin, a protein already known to
interact with survivin (27), was eluted in the same fractions (Fig.
1C). Survivin immunoprecipitated from Raji cell extracts coas-
sociated with Hsp90, by Western blotting, whereas immune
complexes of a control IgG did not contain Hsp90 bands (Fig.
Fig. 1. Survivin–Hsp90 interaction. (A) Heat shock. HeLa cells exposed to 42°C for 1 h were harvested at the indicated time intervals and analyzed by Western
blotting. (B) Cell cycle analysis. HeLa cells were harvested 8 h after heat shock and analyzed for DNA content by flow cytometry. The percentage of G2M cells
is indicated. (C) Affinity purification. HeLa cell extracts were fractionated on a survivin-Sepharose column. Eluted proteins (arrows) were identified by Western
blotting. (D) Coimmunoprecipitation. Raji cell extracts were immunoprecipitated with IgG or an Ab to survivin, and pellets (P) and supernatants (S) were analyzed
by Western blotting. (E) In vivo pull-down. Asynchronous or taxol-treated HeLa cell extracts were incubated with Sepharose (None) or survivin-Sepharose
(Survivin), and pellets or supernatants (25% of reaction) were analyzed for coassociated Hsp90 by Western blotting. MW, molecular weight.
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1D). In pull-down experiments, incubation of asynchronous or
taxol-synchronized HeLa cell extracts with survivin-Sepharose
resulted in coassociation of Hsp90 by Western blotting (Fig. 1E).
StructureFunction of Survivin–Hsp90 Interaction. To begin to iden-
tify the regions in Hsp90 that mediate binding to survivin, we
expressed three regions of Hsp90 to encompass the NH2 termi-
nus domain with the ATP-binding site (N) (12, 14), the middle
domain (M), and the COOH terminus domain (C) as GST
fusion proteins and tested their association with survivin. Only
full-length Hsp90 and its N domain bound recombinant survivin,
whereas the M or C Hsp90 domains had no effect (Fig. 2A).
Immunoprecipitation from HeLa cells transfected with the
various FLAG-Hsp90 domains revealed that endogenous sur-
vivin coassociated with the N domain of Hsp90, but not with the
M or C domains, in vivo (Fig. 2B). Comparable expression of the
individual Hsp90 domains was confirmed by Western blotting of
transfected HeLa cell extracts (Fig. 2B).
To identify the complementary Hsp90-binding site(s) on
survivin, we used partially overlapping synthetic peptides span-
ning the survivin sequence 1–101 (24) to compete the binding
between survivin and Hsp90 in vitro. By ELISA, a Lys-79–Lys-90
survivin peptide completely abrogated the interaction between
the two proteins, whereas none of the other survivin peptides
Fig. 2. Structurefunction of survivin–Hsp90 interaction. (A) In vitro pull-down. Survivin was incubated with Sepharose-GST, -GST-Hsp90, or the indicated
-GST-Hsp90 N, M, or C domains, and protein binding was determined by Western blotting. (B) Immunoprecipitation. HeLa cells transfected with the indicated
FLAG-Hsp90 domains were immunoprecipitated with a mAb to FLAG and analyzed by Western blotting. MW, molecular weight. (C) Peptide mapping. The
indicated survivin peptides were used to compete the binding between Hsp90 and survivin by ELISA. (D) Folding requirement. Protein binding to immobilized
survivin (Upper) or Hsp90 (Lower) was determined by ELISA. (E) In vivo turnover. HeLa cells transfected with GFP-survivin (Left) or GFP-survivin(C84A) (Right) were
treated with cycloheximide, and protein turnover at the indicated time intervals was determined by Western blotting with an Ab to GFP.
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was effective (Fig. 2C). The survivin Lys-79–Lys-90 peptide
bound directly to Hsp90 with high affinity (Kd of 8.38 108 M),
by surface plasmon resonance (data not shown). In the survivin
crystal structure, the Lys-79–Lys-90 sequence connects the third
core  strand of the conserved baculovirus IAP repeat to the -4
and -5 helices, and several of its residues (Lys-79, His-80,
Fig. 3. Regulation of survivin stability by Hsp90. (A) Requirement for Hsp90 chaperone function. HeLa cells were treated with GA and analyzed after 24 h by Western
blotting. MW, molecular weight. (B) Cell cycle analysis. Untreated (Left) or GA-treated (Right) HeLa cells were harvested after 24 h and analyzed for DNA content by
flowcytometry.Thepercentageofcellsateachcell cycle transition is indicated.Apoptotic cellswereelectronicallyexcluded. (C) Proteasomeinhibition.GA-treatedHeLa
cells with or without the proteasome inhibitor lactacystin were analyzed after 30 h by Western blotting. (D) GA-induced apoptosis. GA-treated HeLa cells were analyzed
for plasma membrane integrity (red fluorescence) and caspase-37 activity (green fluorescence) by multiparametric flow cytometry. The percentage of cells in each
quadrant is indicated. (E) Apoptosome requirement. WT or Apaf-1/ MEF were treated with GA and analyzed for apoptosis (Upper) or G2M arrest (Lower) by DNA
content and flow cytometry. (F) Modulation of GA-induced apoptosis. YUSAC-2 cells conditionally expressing survivin after Tet withdrawal (25) were treated with GA
with or without Tet and analyzed for apoptosis by DNA content and flow cytometry. Data in E and F are the means SD of three independent experiments.
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Lys-90, and Lys-91) form a surface-exposed ‘‘basic patch’’ in the
survivin dimer (28).
Folding Requirement of Survivin–Hsp90 Interaction. Because of its
role in protein folding quality control (12, 14), we asked whether
Hsp90 bound mature or unfolded survivin. We expressed a
survivin Cys-843Ala mutant, which disrupts the Zn2 coordi-
nation sphere in the baculovirus IAP repeat and generates an
unfolded survivin molecule. By ELISA, WT survivin bound
avidly to Hsp90 in a concentration-dependent manner, whereas
control CD11b integrin I domain had no effect (Fig. 2D). In
contrast, survivin(C84A) failed to associate with Hsp90 at all
concentrations tested (Fig. 2D), suggesting that folding of sur-
vivin was required for Hsp90 binding. Next, we asked whether
failure to bind Hsp90 correlated with reduced stability of
survivin(C84A) in vivo. In cycloheximide block experiments,
survivin(C84A) exhibited a 5-fold accelerated clearance com-
pared with WT survivin (Fig. 2E), indicating that binding to
Hsp90 may contribute to survivin stability in vivo.
Regulation of Apoptosis and Cell Cycle by Survivin–Hsp90 Interaction.
To test the chaperone function of Hsp90 in survivin binding, we
used the Hsp90 inhibitor GA, which interferes with the ATPase
cycles of the chaperone (29). Treatment of HeLa cells with GA
resulted in concentration-dependent loss of survivin expression
by Western blotting (Fig. 3A). In contrast, Hsp90 levels moder-
ately increased in GA-treated cells, and -actin was unchanged
(Fig. 3A). The effect of GA on survivin levels was not due to cell
cycle arrest before mitosis. Rather, GA induced a G2M arrest
in HeLa cells and no detectable G1 block (Fig. 3B), consistent
with the inactivation of p53Rb in these cells (30). Inhibition of
the chaperone function of Hsp90 results in degradation of client
Fig. 4. Ab disruption of survivin–Hsp90 complex induces apoptosis and cell cycle arrest. (A) In vitro targeting. Survivin was incubated with mAbs 58 or 8E2 to
survivin (24) or IgG, and binding to GST-Hsp90 or GST-N-Hsp90 (GST-Hsp90 N) was determined by Western blotting. (B) In vivo targeting. HeLa cells were loaded
intracellularly with mAb 8E2 or IgG, treated with cycloheximide, and analyzed by Western blotting (Upper). MW, molecular weight. Protein amounts were
quantified by densitometry (Lower). (C) Caspase activity. YUSAC-2 cells loaded with mAb 8E2 or IgG were analyzed for caspase-37 activity by Asp-Glu-Val-Asp
expression and flow cytometry in the absence (Tet) or presence (Tet) of Tet. Data are mean  SD of three independent experiments. (Inset) Proteolytic
processing of caspase-9 in HeLa cells transduced with mAbs 8E2 or 58 to survivin. The positions of proform (Casp.9) or cleaved (Cleaved) caspase-9 are indicated.
(D) Mitotic defects. HeLa cells loaded with mAbs 8E2 or 58 to survivin or IgG were stained with an Ab to -tubulin and analyzed by fluorescence microscopy.
(Magnification, 400.) Multinucleated cells in mAb 8E2-transduced cultures are indicated by arrows. (E) Summary of cell division defects. Mitotic or
multinucleated cells in Ab-transduced HeLa cells were scored by fluorescence microscopy. Data are the means  SEM of four independent determinations.
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proteins through the ubiquitin-proteasome pathway (13). Ac-
cordingly, addition of the proteasome inhibitor lactacystin pre-
vented the loss of survivin induced by GA and resulted in
increased survivin accumulation as compared with untreated
cultures (Fig. 3C). Therefore, the chaperone function of Hsp90
is required for survivin stability in vivo and loss of survivin after
Hsp90 inhibition involves proteasomal-dependent destruction.
Treatment of HeLa cells with GA resulted in concentration-
dependent caspase-mediated apoptosis (Fig. 3D), in a reaction
reversed by the broad-spectrum caspase inhibitor ZVAD-fmk
(data not shown). To discriminate between the effect of GA on
cell cycle progression and cell death, we used MEF-deficient in
the upstream component of mitochondrial-dependent apoptosis,
Apaf-1 (26). GA induced the dose-dependent apoptosis in WT
MEF, but not in Apaf-1/ MEF (Fig. 3E Upper). In contrast,
GA-induced G2M arrest was indistinguishable in WT or Apaf-
1/ MEF (Fig. 3E Lower). These data demonstrate that GA
induces activation of mitochondrial apoptosis and that this
occurs independently from dysregulation of cell cycle progres-
sion. To test whether survivin counteracted apoptosis induced by
Hsp90 inhibition, we used stably transfected YUSAC-2 cells that
conditionally express survivin after withdrawal of Tet (25). In
the presence of Tet, GA-treated YUSAC-2 cells exhibited
concentration-dependent apoptosis (Fig. 3F). In contrast, con-
ditional expression of survivin in Tet-deprived YUSAC-2 cells
(25), suppressed GA-induced apoptosis at all concentrations
tested (Fig. 3F). Therefore, cytoprotection by the survivin–
Hsp90 complex is centered on the mitochondrial pathway, in
agreement with a role of survivin in regulating mitochondrial
apoptosis (31) and caspase-9 recruitment to the Apaf-1 apop-
tosome (32).
Selective Targeting of the Survivin–Hsp90 Interaction Causes Apopto-
sis and Mitotic Defects. To target more selectively the survivin–
Hsp90 complex, we identified mAb 8E2 to survivin (24), which
abolished the binding of survivin to Hsp90 or its N domain in
vitro (Fig. 4A). In contrast, another Ab to survivin, mAb 58 (24),
or nonimmune IgG, had no effect (Fig. 4A). Intracellular
delivery of mAb 8E2 resulted in progressive loss of survivin
expression in cycloheximide block experiments, whereas IgG did
not affect survivin levels (Fig. 4B). Intracellular loading of mAb
8E2, but not IgG or mAb 58, resulted in increased caspase-37
activity in Tet-containing YUSAC-2 cultures (Fig. 4C) and
proteolytic processing of caspase-9 in HeLa cells (Fig. 4C Inset).
Conditional expression of survivin in Tet-deprived YUSAC-2
cells suppressed caspase-37 activity induced by mAb 8E2 (Fig.
4C). HeLa cells loaded with mAb 8E2 exhibited profound
inhibition of cell proliferation and appearance of multinucleated
cells as compared with IgG- or mAb 58-loaded cultures (Fig. 4
D and E). These data are consistent with a dual role of survivin
in cytoprotection (32) and mitotic transition (23).
In summary, we identified the IAP family member (3) survivin
as a new client protein for Hsp90 (14, 15), linking the cellular
stress response to a dual cell viabilitymitotic checkpoint. Be-
cause the conserved survivin baculovirus IAP repeat (3) con-
tains the Hsp90-binding site, it is possible that Hsp90 recognition
may involve other IAPs and thus affect their stability and
maturation. This may have profound repercussions for cell
viability because sudden losses in IAP expression trigger apo-
ptosis (33), and mechanisms controlling IAP degradation reg-
ulate cell death (34). The association of survivin with Hsp90 may
be required to accommodate its multiple molecular interactions
(32) and dynamic subcellular localizations (24) required for cell
deathmitotic regulation (23). In tumors, where both survivin
and Hsp90 are up-regulated (16, 23), this interaction may
provide a broad permissive environment (18, 21), inhibiting
apoptosis (32) and obliterating mitotic checkpoints (24). Con-
versely, molecular antagonists of the survivin–Hsp90 interaction
may provide a rational approach to critically lower this antiapo-
ptotic threshold and promote targeted elimination of cancer
cells.
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